Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Second-Eye gene therapy offers hope for rare vision loss

NCT ID NCT06646289

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times

Summary

This study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The therapy uses a harmless virus to deliver a working gene to the retina. Researchers will check safety and whether it improves vision in 24 adults and children who already received treatment in one eye.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts, 02114, United States

  • Moorfields Eye Hospital

    London, EC1V 2PD, United Kingdom

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan, 48105, United States

Conditions

Explore the condition pages connected to this study.